2014-06-17 20:07:56 UTC

Therapeutic Treatment for Celiac Disease Proves Effective in Phase 2 Trial

June 19, 2014

Marja-Leena Lähdeaho and colleagues report in Gastroenterology that the glutenase ALV003 appears to attenuate gluten-induced small intestinal mucosal injury in patients with celiac disease in the context of an everyday gluten-free diet containing daily up to 2 g gluten.

Gluten ingestion leads to small intestinal mucosal injury in patients with celiac disease, necessitating strict life-long exclusion of dietary gluten. Despite adherence to a gluten-free diet, many patients remain symptomatic and still have small intestinal inflammation. In this case, nondietary therapies are needed. Marja-Leena Lähdeaho and colleagues investigated the ability of ALV003, a mixture of two recombinant gluten-specific proteases given orally, to protect patients with celiac disease from gluten-induced mucosal injury in a phase II trial. They report in Gastroenterology that the glutenase ALV003 appears to attenuate gluten-induced small intestinal mucosal injury in patients with celiac disease in the context of an everyday gluten-free diet containing daily up to 2 g gluten.

Gastroenterology 2014: 146(7): 1649-1658

More on Celiac Disease

Course for APPs benefits all experience levels

April 16, 2018

AGA's popular course for advanced practice providers will take place Aug. 10 through 12 in Chicago, Illinois.

APPs: Enhance your delivery of patient care

March 28, 2018

AGA's popular course for advanced practice providers will be held this summer in Chicago.

HLA-DQ–Gluten Tetramer Blood Test Accurately Identifies Patients With and Without Celiac Disease in Absence of Gluten Consumption

March 1, 2018

An HLA-DQ–gluten tetramer based assay that detects gluten-specific T cells accurately identifies patients with and without celiac disease, regardless of whether the individuals are on a gluten-free diet.